A multifunctional non-viral vector for the delivery of MTH1-targeted CRISPR/Cas9 system for non-small cell lung cancer therapy

清脆的 Cas9 生物 遗传增强 病毒载体 基因组编辑 基因传递 质粒 核酸酶 癌症研究 计算生物学 基因 遗传学 重组DNA
作者
Yu Wang,Yuzhe Tang,Xiaomei Zhao,Gui Huang,Jinhong Gong,Shu-di Yang,Hui Li,Wenjun Wan,Chang-Hao Jia,Gang Chen,Xuenong Zhang
出处
期刊:Acta Biomaterialia [Elsevier]
卷期号:153: 481-493 被引量:19
标识
DOI:10.1016/j.actbio.2022.09.046
摘要

Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) system adapted from bacteria is a programmable nuclease-based genome editing tool. The long-lasting effect of gene silencing or correction is beneficial in cancer treatment. Considering the need to broaden the practical application of this technology, highly efficient non-viral vectors are urgently required. We prepared a multifunctional non-viral vector that could actively target tumor cells and deliver CRISPR/Cas9 plasmids into nuclei of cancer cells. Protamine sulfate (PS) which contains nuclear localization sequence was utilized to condense plasmid DNA and facilitate nuclei-targeted delivery. Liposome-coated protein/DNA complex avoided the degradation of nuclease in blood circulation. The obtained PS@Lip/pCas9 was further modified with distearoyl phosphoethanolamine-polyethylene glycol-hyaluronic acid (HA) to endow the vector ability to actively target tumor cell. Results suggested that PS@HA-Lip could deliver CRISPR/Cas9 plasmids into nuclei of tumor cells and induce genome editing effect. With the disruption of MTH1 (mutT homolog1) gene, the growth of non-small cell lung cancer was inhibited. Moreover, cell apoptosis in tumor tissue was promoted, and liver metastasis of non-small cell lung cancer (NSCLC) was reduced. Our study has provided a therapeutic strategy targeting MTH1 gene for NSCLC therapy. STATEMENT OF SIGNIFICANCE: CRISPR/Cas9 as a powerful tool for genome editing has drawn much attention. The long-lasting effect possesses unique advantage in cancer treatment. Non-viral vectors have high loading capacity, high safety and low immunogenicity, playing an important role in CRISPR/Cas9 delivery. In our study, a multifunctional non-viral vector for the efficient delivery of CRISPR/Cas9 plasmid was constructed. With the active targeting ligand and nuclei-targeting component, the cargo was efficiently delivered into cell nuclei and exerted genome editing effect. By using this vector, we successfully inhibited the growth and induced the apoptosis of non-small cell lung cancer by disrupting MTH1 expression with good safety. Our work provided an efficient non-vial vector for CRISPR/Cas9 delivery and explored the possibility for cancer treatment.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
深情安青应助Y.B.Cao采纳,获得10
1秒前
静仰星空发布了新的文献求助10
2秒前
酷波er应助zz采纳,获得10
2秒前
苏苏发布了新的文献求助20
3秒前
宁阿霜发布了新的文献求助10
3秒前
4秒前
tong完成签到,获得积分10
4秒前
我要发论文!!!!完成签到,获得积分10
4秒前
4秒前
4秒前
5秒前
耍酷大炮完成签到,获得积分10
5秒前
甜北枳完成签到,获得积分10
5秒前
雪雪儿发布了新的文献求助10
5秒前
宵荷完成签到,获得积分10
6秒前
活泼凌青完成签到,获得积分10
6秒前
酷波er应助suofzcn采纳,获得10
6秒前
学术奋变完成签到,获得积分10
6秒前
7秒前
Anonymous完成签到,获得积分10
7秒前
敏感冷玉发布了新的文献求助10
7秒前
C居发布了新的文献求助30
8秒前
czy完成签到,获得积分10
8秒前
8秒前
10秒前
Khan发布了新的文献求助10
10秒前
孤僻发布了新的文献求助10
10秒前
共享精神应助默默的荔枝采纳,获得80
11秒前
Lida完成签到,获得积分10
11秒前
11秒前
葭月十七发布了新的文献求助30
12秒前
13秒前
13秒前
14秒前
Zz发布了新的文献求助10
14秒前
loong发布了新的文献求助10
15秒前
YHK完成签到,获得积分10
15秒前
15秒前
liujunhong关注了科研通微信公众号
17秒前
高分求助中
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
юрские динозавры восточного забайкалья 800
Foreign Policy of the French Second Empire: A Bibliography 500
Chen Hansheng: China’s Last Romantic Revolutionary 500
XAFS for Everyone 500
Classics in Total Synthesis IV 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3144189
求助须知:如何正确求助?哪些是违规求助? 2795795
关于积分的说明 7816709
捐赠科研通 2451879
什么是DOI,文献DOI怎么找? 1304729
科研通“疑难数据库(出版商)”最低求助积分说明 627286
版权声明 601419